Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company, has reported a recent insider transaction. According to a filing with the Securities and Exchange Commission, ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Neurocrine Biosciences amended its Takeda agreement, gaining exclusive global rights to osavampator for major depressive disorder. Phase 2 data for osavampator showed significant MADRS score ...